PRESS: Global Genes

Forge Biologics, a viral vector gene therapy manufacturing and development company with a platform to develop proprietary gene therapy products, has launched with $40 million in series A financing.

Perceptive Xontogeny Venture Fund led the funding with participation from Drive Capital. Forge will use the proceeds to expand AAV and for the development of a novel gene therapy pipeline.

Read In Full:

https://globalgenes.org/2020/07/21/forge-biologics-launches-with-40-million-to-manufacture-and-develop-gene-therapies/